BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 21142269)

  • 21. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
    Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
    Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations.
    Karonen T; Laitila J; Niemi M; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2012 May; 68(5):681-8. PubMed ID: 22108774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
    Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
    Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
    Weiss J; Sawa E; Riedel KD; Haefeli WE; Mikus G
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):275-82. PubMed ID: 18516595
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects.
    Park JY; Shon JH; Kim KA; Jung HJ; Shim JC; Yoon YR; Cha IJ; Shin JG
    J Clin Psychopharmacol; 2006 Apr; 26(2):135-42. PubMed ID: 16633141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone.
    Potkin SG; Preskorn S; Hochfeld M; Meng X
    J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the novel anxiolytic drug deramciclane on cytochrome P(450) 2D6 activity as measured by desipramine pharmacokinetics.
    Laine K; De Bruyn S; Björklund H; Rouru J; Hänninen J; Scheinin H; Anttila M
    Eur J Clin Pharmacol; 2004 Feb; 59(12):893-8. PubMed ID: 14730412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
    Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
    Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of cytochrome 3A4 and 2D6-mediated drug-drug interactions in oxycodone consumption among older adults hospitalized for hip fracture: a cross-sectional study.
    Decaix T; Gautier S; Royer L; Laprévote O; Tritz T; Siguret V; Teillet L; Sellier C; Pépin M
    Aging Clin Exp Res; 2023 Nov; 35(11):2471-2481. PubMed ID: 37861957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
    Tsukada H; Chen YL; Xiao G; Lennek L; Milanovic SM; Worden M; Polhamus DG; Chiu YY; Hopkins SC; Galluppi GR
    Clin Pharmacokinet; 2023 Dec; 62(12):1755-1763. PubMed ID: 37882999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: reversible inhibition by H2-receptor agonists and proton-pump inhibitors.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2013 Oct; 37(8):476-85. PubMed ID: 23857299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
    Rytkönen J; Ranta VP; Kokki M; Kokki H; Hautajärvi H; Rinne V; Heikkinen AT
    Biopharm Drug Dispos; 2020 Feb; 41(1-2):72-88. PubMed ID: 31925778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I open-label study to investigate the potential drug-drug interaction between single-dose dacomitinib and steady-state paroxetine in healthy volunteers.
    Ruiz-Garcia A; Giri N; LaBadie RR; Ni G; Boutros T; Richie N; Kocinsky HS; Checchio TM; Bello CL
    J Clin Pharmacol; 2014 May; 54(5):555-62. PubMed ID: 24293056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol.
    Laugesen S; Enggaard TP; Pedersen RS; Sindrup SH; Brøsen K
    Clin Pharmacol Ther; 2005 Apr; 77(4):312-23. PubMed ID: 15903129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro.
    Wang JS; DeVane CL
    Drug Metab Dispos; 2003 Jun; 31(6):742-7. PubMed ID: 12756206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.